Chronic liver diseases are a significant cause of death worldwide. Cirrhosis is most frequently caused by hepatitis C or alcohol abuse, but other nonviral etiologies are now recognized as important contributors to the development of hepatitis. Nonalcoholic fatty liver disease, caused by abnormal accumulation of lipids in hepatocytes, can progress from simple steatosis to necroimflammation and cirrhosis. It is estimated to occur in up to 40% of the general population, and its pathophysiology is closely linked to features of metabolic syndrome. There is currently no proven treatment for nonalcoholic fatty liver disease. Management strategies largely address identification and treatment of associated risk factors and include drug therapy for obesity, insulin resistance (eg, metformin, thiazolidinediones), and dyslipidemia (eg, fibrates, HMG-CoA reductase inhibitors). Autoimmune hepatitis is characterized by necroinflammation mediated by autoantibody attack against liver antigens in genetically predisposed patients. It is considered a rare form of chronic liver disease but can progress to cirrhosis if unrecognized and untreated. Autoimmune hepatitis usually responds well to long-established immunosuppressive regimens with prednisone and azathioprine; however, new approaches are required for those patients who do not achieve or sustain desired outcomes or are intolerant to standard therapy.
Clark JMThe epidemiology of non-alcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006; 40(suppl 1):S5-S10.
6.
Kowdley KV, Caldwell S.Nonalcoholic steatohepatitis. A twenty-first century epidemic?J Clin Gastroenterol. 2006; 40(suppl 1):S2-S4.
7.
Chitturi S., Farrell GC, Hashiomoto E., et al. Nonalcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastro Hepatol. 2007;22:778-787.
8.
Day CP, James OFSteatohepatitis: a tale of two ``hits''? Gastroenterology . 1998;11:842-845.
Browning JD , Horton JDMolecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114: 147-152.
11.
Diehl AM, Li ZP, Lin HZ, et al. Cytokines and the pathogenesis of non-alcoholic steatohepatitis . Gut. 2005;54: 303-306.
12.
Calamita G. , Portincasa P.Present and future therapeutic strategies in non-alcoholic fatty liver disease. Expert Opin Ther Targets . 2007;11:1231-1249.
13.
Diakou MC, Liberopoulos EN, Mikhailidis DP, et al. Pharmacological treatment of non-alcoholic steatohepatitis: The current evidence. Scand J Gastroenterol. 2007; 42:139-147.
14.
Angulo P.NAFLD, obesity, and bariatric surgery. Gastroenterology . 2006;130:1848-1852.
15.
American Gastroenterological Association.A technical review of non-alcoholic fatty liver disease. Gastroenterology. 2002 ;123:1705-1725.
16.
Angulo P.Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231.
17.
Bacon BR, Farahvash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;2:303-313.
18.
Tarantino G. , Saldalamacchia G., Conca P., et al. Non-alcoholic fatty liver diseae: further expression of the metabolic syndrome. J Gastro Hepatol . 2007;22: 293-303.
19.
Ipekci SH, Basaranoglu M., Sonsuz A.The fluctuation of serum levels of aminotransferase in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol. 2003 ;36: 371.
20.
Joy D., Thava VR, Scott BBDiagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol. 2003;15:539-543.
21.
Saadeh S., Younossi ZM, Remer EM, et al. The utility of radiological imaging in non-alcoholic fatty liver disease. Gastroenterology. 2002;123:745-750.
22.
Ratziu V., Charlotte H., Heurtier A., et al. High sampling variability of percutaneous liver biopsy in non-alcoholic fatty liver disease. Gastroenterology. 2005 ;128: 1898-1906.
23.
Neuschwander Tetri BA, Caldwell SHNonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37:1202-1219.
24.
Chan HLY , de Silva J., Leung NWY , et al, and the Asia-Pacific Working Party on NAFLD. How should we manage patients with non-alcoholic fatty liver disease in 2007?J Gastro Hepatology.2007;22:801-808.
Menshikova EV , Ritov VB, Toledo FG, et al. Effects of weight loss and physical activity on skeletal muscle mitochondrial function in obesity . Am J Physiol Endocrinol Metab.2005;288;(4):818-825.
29.
Shaffer EABariatric surgery: a promising solution for nonalcoholic steatohepatitis in the very obese. J Clin Gastroenterol. 2006 ;40:S44-S50.
30.
National Heart Blood and Lung Institute.Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. NIH; 2000.
31.
Padwal R., Li SK, Lau DCW. (Updated August 20, 2003). Long-term pharmacotherapy for obesity and overweight [Cochrane Review]. Cochrane Database Syst Rev.2008;1. Retrieved February 8, 2008 from Ovid Evidence Based Medicine Reviews: Cochrane Database of Systematic Reviews.
32.
Harrison SA , Fincke C., Helinski D., et al. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther. 2004;20: 623-628.
33.
Hatzitolios A., Savopoulous C., Lazaraki G., et al. Efficacy of omega-3-fatty acids, atorvastatin and orlistat in nonalcoholci fatty liver disease with dyslipidemia. Indian J Gastroenterol. 2004;23:131-134.
34.
Zelber-Sagi S., Kessler A., Brazowsky E., et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol.2006;4:639-644.
35.
Sabuncu T., Nazliguly Y., Karaoglanoglu M., et al. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance, and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol. 2003;12:189-192.
36.
Despres JP, Golay A., Sjostrom L.Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121-2134.
37.
Caldwell SH , Argo CK, Al-Osaimi AMS.Therapy of NAFLD. Insulin sensitizing agents . J Clin Gastroenterol. 2006;40(suppl 1):S61-S66.
38.
Coyle WJ, Delaney N., Yoshihashi A.Metformin treatment in patients with nonalcoholic steatohepatitis normalizes LFTs and improves histology [abstract]. Gastroenterology . 1999;116:A1198.
39.
Marchesini G., Brizi M., Bianchi G., et al. Metformin in non-alcoholic steatohepatitis . Lancet. 2001 ;358: 893-894.
40.
Duseja A., Murlidharan R., Bhansali A., et al. Assessment of insulin resistance and effect of metformin in nonalcoholic steatohepatitis-a preliminary report. Indian J Gastroenterol. 2004;23:12-15.
41.
Nair S., Diehl AM, Wiseman M., et al. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004;20: 23-28.
42.
Uygun A., Kadayifci A., Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis . Aliment Pharmacol Ther. 2004;19:537-544.
43.
Schwimmer JB , Middleton MS, Deutsch R., et al. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2005;21:871-879.
44.
Bugianesi E. , Gentilcore E., Manini R., et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease . Am J Gastroenterol. 2005;100:1082-1090.
45.
Loomba R., Lutrchman G., Kleiner D.Pilot study of metformin in patients with non-alcoholic steatohepatitis [abstract] . Hepatology. 2006;44(suppl 1):260A.
46.
Caldwell SH , Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol . 2001;96: 519-525.
47.
Acosta RC, Molina EG, O'Brien CBThe use of pioglitazone in nonalcoholic steatohepatits [abstract] . Gastroenterology. 2001;120:A546.
48.
Shadid S., Jensen MDEffect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. Clin Gastroenterol Hepatol . 2003;1:384-387.
49.
Promrat K., Lutchman G., Uwaifo GI, et al. A pilot study of pioglitazone treatment for non-alcoholic steatohepatitis . Hepatology. 2004;39:188-196.
50.
Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitzone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2004;2:1107-1115.
51.
Belfort R., Harrison SA, Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297-2307.
52.
Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone . Hepatology. 2003;38:1008-1017.
53.
Tikkainen M. , Hakkinen AM, Korsheninnikova E., et al. Effects of rosiglitzone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patient with type 2 diabetes. Diabetes. 2004;53:2169-2176.
54.
Ratziu V., Charlotte F., Jacquemimet S.A one year randomized, placebo-controlled double-blind trial of rosiglitazone in non-alcoholic steatohepatitis: results of the FLIRT pilot trial [abstract] . Hepatology. 2006;44 (suppl 1):201A.
55.
Lin HZ, Yang SQ, Chuckaree C., et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000;6:998-1003.
56.
Non-alcoholic fatty liver disease. Available at: http://clinicaltrials.gov. Accessed May 2, 2008.
57.
Lutchman G. , Promrat K., Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Is long-term therapy needed?Hepatology. 2007;46:424-429.
58.
McCullough AJThiazolidinediones for non-alcoholic steatohepatitis-promising but not ready for prime time. N Engl J Med. 2006;355:2297-2307.
59.
Laurin J., Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of nonalcoholic-induced steatohepatitis: a pilot study. Hepatology. 1996;23:1464-1467.
60.
Basaranoglu M. , Acbay O., Sonsuz A.A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis (letter). J Hepatol. 1999;31: 384.
61.
Kiyici M., Gulten M., Gurel S., et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol. 2003 ;17:713-718.
62.
Georgescu EF , Georgescu M.Therapeutic options in non-alcoholic steatohepatisi (NASH). Are all agents alike? Results of a preliminary study . J Gastrointestin Liver Dis.2007;16:39-46.
63.
Gomez-Dominguez E., Gisbert JP, Moreno-Monteagudo JA, et al. A pilot study of atrovastatin treatment in dyslipidemia, non-alcoholic fatty liverpatients . Aliment Pharmacol Ther. 2006;23:1643-1647.
64.
Rallidis LS , Drakoulis CK, Parasi ASPravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Artherosclerosis . 2004;174:193-196.
65.
Chalasani N.Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology. 2005;41:690-695.
66.
Merat S., Malekzadeh R., Sohrabi MR, et al. Probuchol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol. 2003;38: 414-418.
67.
Capanni M., Calella F., Biagini MR, et al. Prolonged n-3 polyunsaturated fatty acids supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther. 2006;23: 1143-1151.
68.
Lazaridis KN , Gores GJ, Lindor KDUrsodeoxycholic acid mechanisms of action and clinical use in heptobiliary disorders. J Hepatol. 2001;35:134-146.
69.
Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39: 770-778.
70.
Vajro P., Franzese A., Valerio G., et al. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr. 2000;136:739-743.
71.
Mendez-Sanchez N., Gonzalez V., Chavez-Tapia N., et al. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial. Ann Hepatol.2004;3:108-112.
72.
Orlando R., Azzalini L., Orlando S., et al. (Updated February 19, 2007). Bile acids for non-alcoholic fatty liver disease and /or steatohepatitis. [Cochrane Review]. Cochrane Database Syst Rev.2007;1. Retrieved February 8, 2008 from Ovid Evidence Based Medicine Reviews: Cochrane Database of Systematic Reviews.
73.
Lavine JEVitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study . J Pediatr. 2000;136: 734-738.
74.
Hasegawa T. , Yoneda M., Nakamura K., et al. Plasma transforming growth factor-β1 level and efficacy of αtocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther. 2001 ;15: 1667-1672.
75.
Harrison SA , Torgerson S., Hayashi P., et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis . Am J Gastroenterol. 2003;98:2485-2490.
76.
Guallar E., Hanley DF, Miller Eriii.An editorial update: annus horribilis for vitamin E. Ann Intern Med. 2005;143: 143-145.
77.
Lirussi F., Azzalini L., Orando S., et al. (Updated November 15, 2006). Antioxidant supplementation for nonalcoholic fatty liver disease and/or steatohepatitis [Cochrane Review] . In Cochrane Database Syst Rev.2007;1. Retrieved February 8, 2008 from Ovid Evidence Based Medicine Reviews: Cochrane Database of Systematic Reviews.
78.
Boberg KMPrevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis. 2002;6:635-647.
79.
American Liver Foundation. Available at: http://www.liverfoundation.org/. Accessed May 2, 2008.
80.
Krawitt ELAutoimmue hepatitis. N Engl J Med. 2006;354:54-66.
Czaja AJ, Mannus MPThe validity and importance of subtypes of autoimmune hepatitis: a point of view. Am J Gastroenterol. 1995;90:1206-1211.
84.
Homberg JC, Abuaf N., Bernard O., et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of ``autoimmune'' hepatitis. Hepatology. 1987;7:1333-1339.
85.
Wolf DCAutoimmune hepatitis. Available at: http://www.emedicine.com/med/topic366.htm . Accessed April 28, 2008 .
86.
Czaja AJ, Freese DKDiagnosis and treatment of autoimmune hepatitis. AASLD Practice Guidelines . Hepatology. 2002;36:479-497.
87.
Soloway RD, Hewlett ATThe medical treatment for autoimmune hepatitis through corticosteroid to new immunosuppressive agents: a concise review. Ann Hepatol . 2007;6:204-207.
88.
Soloway RD, Summerskill WHJ, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of servere chronic active liver disease: a controlled study of treatments and early prognosis . Gastroenterology. 1972; 63:820-833.
Summerskill WHJ , Korman MG, Ammon HV, et al. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut. 1975;16:876-883.
91.
Gish RB, Mason A.Autoimmune liver disease. Current standards, future directions. Clin Liv Dis.2001;5: 287-314.
Ryder SD, Richardson PD, James PDMycophenolate mofetil for maintenance in autoimmune hepatitis in patients resistant to or intolerant to azathioprine. J Hepatol. 2000;33:371-375.
